Teva (NYSE:TEVA) will be responsible for potential commercialization of Uzedy for BP-I. Medincell will be eligible for royalties on net sales. The FDA approved Uzedy for the treatment of ...

Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd, and Medincell announced that the supplemental New Drug Application (sNDA) for Uzedy extended-release injectable suspension ...

New data presented by Teva at ECNP 2024* demonstrate switching to UZEDY at four weeks after the last dose of once-monthly Perseris® (RBP-7000) provided the most comparable pharmacokinetic (PK ...

Branded drugs like Austedo and Uzedy face challenges, with Austedo's future revenue potentially affected by IRA negotiations and tepid growth projections for Ajovy and Uzedy. Teva's experimental ...

and is now distributed in the United States by Teva under the name UZEDY® (BEPO® technology is licensed to Teva under the name SteadyTeq™). We collaborate with leading pharmaceutical companies ...